Literature DB >> 27182648

Histologic Disease in Chinese Chronic Hepatitis B Patients With Low Viral Loads and Persistently Normal Alanine Aminotransferase Levels.

Hong Wang1, Guo Qing Ru, Rong Yan, Yin Zhou, Ming Shan Wang, Mei Juan Cheng.   

Abstract

BACKGROUND/AIM: We aimed to evaluate the histopathologic characteristics of HBeAg-negative chronic hepatitis B patients with low hepatitis B virus (HBV) DNA levels (<2000 IU/mL) and persistently normal ALT levels and to determine indicators of significant liver disease.
METHODS: We examined 102 consecutive subjects who underwent percutaneous liver biopsy. Significant predictors of liver disease (stage ≥2 fibrosis or stage 1 fibrosis plus grade ≥2 inflammation), including demographic, clinical, and laboratory variables, were evaluated by means of univariate and multivariate logistic regression analyses.
RESULTS: Among the patients, 75.5% (77/102) had grade 0-1 inflammation and 77.5% (79/102) had stage 0-1 fibrosis. However, 38.2% (39/102) had significant liver disease. There were no statistically significant differences in clinical parameters such as age, biochemical profile, HBV DNA levels, HBsAg levels, and platelet count between patients with significant and those with nonsignificant liver disease. Patients with significant liver disease had higher values of aspartate transferase-to-platelet ratio index (APRI) and FIB-4 index compared with those with nonsignificant liver disease (0.35±0.21 vs. 0.27±0.12, P=0.02; 1.58±0.97 vs. 1.13±0.54, P=0.009, respectively). The area under the receiver operating characteristic (AUROC) curve of APRI for identifying active liver histology was 0.64 (95% CI, 0.53-0.75; P=0.019); the cutoff value was 0.24 with a sensitivity of 74% and specificity of 55%. In comparison, FIB-4 had equal power (the AUROC was 0.66) in predicting active liver histology.
CONCLUSION: Among patients presenting with low HBV DNA levels and normal ALT levels, about 38.2% had significant liver disease. Neither serum HBsAg nor HBV DNA levels correlate with liver histology. However, APRI≥0.24 might be considered an indicator of liver biopsy.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27182648     DOI: 10.1097/MCG.0000000000000544

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  12 in total

1.  Advantages of a Novel Model for Predicting Hepatic Fibrosis in Chronic Hepatitis B Virus Carriers Compared with APRI and FIB-4 Scores.

Authors:  Na-Ling Kang; Qing-Fa Ruan; De-Sheng Zhang; Xue-Ping Yu; Zhen-Ting Hu; Zhi-Min Lin; Lu-Ying Wu; Meng-Xin Lin; Zu-Xiong Huang; Jia-Ji Jiang; Yu-Rui Liu; Ri-Cheng Mao; Da-Wu Zeng
Journal:  J Clin Transl Hepatol       Date:  2022-06-01

2.  The expression of thymosin β4 in chronic hepatitis B combined nonalcoholic fatty liver disease.

Authors:  Jing Liang; Wenjuan Cai; Tao Han; Li Jing; Zhe Ma; Yingtang Gao
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.889

3.  Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis.

Authors:  Milan J Sonneveld; Willem P Brouwer; Bettina E Hansen; Henry L-Y Chan; Teerha Piratvisuth; Ji-Dong Jia; Stefan Zeuzem; Rong-Nan Chien; Hannah Choi; Robert J de Knegt; Cynthia Wat; Vedran Pavlovic; Anuj Gaggar; Qing Xie; Maria Buti; Robert A de Man; Harry L A Janssen
Journal:  Aliment Pharmacol Ther       Date:  2020-09-04       Impact factor: 8.171

4.  Unreliable Estimation of Fibrosis Regression During Treatment by Liver Stiffness Measurement in Patients With Chronic Hepatitis B.

Authors:  Dong Ji; Yan Chen; Qinghua Shang; Huabao Liu; Lin Tan; Jing Wang; Yongping Chen; Qin Li; Qinghua Long; Laicheng Song; Li Jiang; Guangming Xiao; Zujiang Yu; Liang Chen; Xiaoyu Hu; Xiaodong Wang; Da Chen; Zhiqin Li; Zheng Dong; Guofeng Chen; Yongping Yang
Journal:  Am J Gastroenterol       Date:  2021-04-08       Impact factor: 10.864

5.  The clinical value of serum hepatic parenchyma cell volume-normalized hepatitis B surface antigen levels in hepatitis B e antigen -positive and -negative chronic hepatitis B patients.

Authors:  Lei Tan; Shi-Lei Xu; Zhi-Shuo Mo; Jian-Rong Liu; Wei-Qiang Gan; Jie-Huan Chen; Zhi-Liang Gao; Ze-Qian Wu
Journal:  Ann Transl Med       Date:  2021-09

6.  Effectiveness of Tenofovir Alafenamide in Chronic Hepatitis B Patients with Normal Alanine Aminotransferase and Positive Hepatitis B Virus DNA.

Authors:  Wen-Kang Gao; Yan-Yun Shu; Yue Chen; Yan Ai; Xiao-Qian Yang; Fan Du; Jin Ye
Journal:  J Clin Transl Hepatol       Date:  2021-06-15

7.  The Role of Metabolic Factors and Steatosis in Treatment-Naïve Patients with Chronic Hepatitis B and Normal Alanine Aminotransferase.

Authors:  Hongwu Wang; Qin Ning; Yuting Diao; Danqing Hu; Xue Hu; Peng Wang; Xiaojing Wang; Xiaoping Luo
Journal:  Infect Dis Ther       Date:  2022-04-10

8.  Disease burden of chronic hepatitis B and complications in China from 2006 to 2050: an individual-based modeling study.

Authors:  Yang Zheng; Jie Wu; Cheng Ding; Kaijin Xu; Shigui Yang; Lanjuan Li
Journal:  Virol J       Date:  2020-08-28       Impact factor: 4.099

9.  Clinical and histopathological features of chronic hepatitis B virus infected patients with high HBV-DNA viral load and normal alanine aminotransferase level: A multicentre-based study in China.

Authors:  Yu-Feng Xing; Da-Qiao Zhou; Jing-Song He; Chun-Shan Wei; Wei-Chao Zhong; Zhi-Yi Han; De-Ti Peng; Mu-Min Shao; Tung-Ting Sham; Daniel Kam-Wah Mok; Chi-On Chan; Guang-Dong Tong
Journal:  PLoS One       Date:  2018-09-04       Impact factor: 3.240

10.  Necro-inflammatory activity grading in chronic viral hepatitis with three-dimensional multifrequency MR elastography.

Authors:  Philippe Garteiser; Gwenaël Pagé; Gaspard d'Assignies; Helena S Leitao; Valérie Vilgrain; Ralph Sinkus; Bernard E Van Beers
Journal:  Sci Rep       Date:  2021-09-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.